Key Highlights
- $105M equity raise led by The Rise Fund to extend commercialization of SCINTIX® therapy.
- SCINTIX® therapy aims to treat all stages of indicated solid tumor cancers, including metastatic disease.
- Investment supported by prominent organizations like Pfizer Ventures, Johnson & Johnson Innovation, and T.Rowe Price Associates.
Source: Business Wire
Notable Quotes
- “Closing an equity round of this size strongly affirms the conviction of our new and existing investors in fueling innovation for breakthrough treatment options, like SCINTIX therapy, in the battle against cancer,” – Todd Powell, President and CEO at RefleXion Medical
- “We are delighted to see RefleXion reach a stage where they can accelerate their impact and deliver treatment and outcomes at scale,” – Matthew Hobart, Co-Managing Partner at TPG Growth
SoH's Take
The substantial $105M equity raise by RefleXion Medical, under the leadership of The Rise Fund, represents a pivotal moment in the field of therapeutic oncology. This investment not only highlights the growing confidence in innovative cancer treatments but also marks a significant leap forward for SCINTIX® therapy. SCINTIX’s unique approach in targeting and managing motion in radiotherapy, particularly for metastatic disease, is poised to revolutionize cancer treatment. The involvement of heavyweight investors and pharmaceutical leaders further underscores the potential of RefleXion’s technology to transform oncology practices. This move could potentially redefine standards in cancer care, offering hope to patients across various stages of cancer.
